These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7061864)

  • 21. A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 Streptococcus pneumoniae.
    Edwards KM; Gewurz H; Lint TF; Mold C
    J Immunol; 1982 Jun; 128(6):2493-6. PubMed ID: 7077077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitric oxide exerts distinct effects in local and systemic infections with Streptococcus pneumoniae.
    Kerr AR; Wei XQ; Andrew PW; Mitchell TJ
    Microb Pathog; 2004 Jun; 36(6):303-10. PubMed ID: 15120156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Streptococcus pneumoniae: proteomics of surface proteins for vaccine development.
    Morsczeck C; Prokhorova T; Sigh J; Pfeiffer M; Bille-Nielsen M; Petersen J; Boysen A; Kofoed T; Frimodt-Møller N; Nyborg-Nielsen P; Schrotz-King P
    Clin Microbiol Infect; 2008 Jan; 14(1):74-81. PubMed ID: 18034862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against bacteremic pneumococcal infection by antibody to pneumolysin.
    Musher DM; Phan HM; Baughn RE
    J Infect Dis; 2001 Mar; 183(5):827-30. PubMed ID: 11181163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized and can protect splenectomized mice from infection with Streptococcus pneumoniae.
    Coats MT; Benjamin WH; Hollingshead SK; Briles DE
    Vaccine; 2005 Jul; 23(33):4257-62. PubMed ID: 16005736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-Reactive Protein-Based Strategy to Reduce Antibiotic Dosing for the Treatment of Pneumococcal Infection.
    Ngwa DN; Singh SK; Agrawal A
    Front Immunol; 2020; 11():620784. PubMed ID: 33552084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of an immunomodulating drug in immunodeficient and immunocompetent mice.
    Mago S; Gerlach GF; Petzoldt K
    Comp Immunol Microbiol Infect Dis; 1988; 11(1):43-50. PubMed ID: 3133156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Changes in c-reactive proteins, fibrinogenesis and transaminase in coronary insufficiency].
    Khvatova EA; Romanovskaia VK
    Vrach Delo; 1965 May; 5():47-9. PubMed ID: 5856583
    [No Abstract]   [Full Text] [Related]  

  • 32. Protective activity of normal chicken serum in Klebsiella pneumoniae infection.
    Picoff ER
    J Infect Dis; 1966 Feb; 116(1):27-32. PubMed ID: 5908852
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular genetics, structure, and function of C-reactive protein.
    Kilpatrick JM; Volanakis JE
    Immunol Res; 1991; 10(1):43-53. PubMed ID: 1865130
    [No Abstract]   [Full Text] [Related]  

  • 34. [Mortality in pneumococcal disease].
    Pallarés R
    Med Clin (Barc); 2004 Oct; 123(15):578-9. PubMed ID: 15535940
    [No Abstract]   [Full Text] [Related]  

  • 35. C-reactive protein: structure, function, regulation, and role in clinical diseases.
    Zhou HH; Tang YL; Xu TH; Cheng B
    Front Immunol; 2024; 15():1425168. PubMed ID: 38947332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein - My perspective on its first half century, 1930-1982.
    Kushner I
    Front Immunol; 2023; 14():1150103. PubMed ID: 36936978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish.
    Saralahti AK; Harjula SE; Rantapero T; Uusi-Mäkelä MIE; Kaasinen M; Junno M; Piippo H; Nykter M; Lohi O; Rounioja S; Parikka M; Rämet M
    PLoS Genet; 2023 Jan; 19(1):e1010586. PubMed ID: 36622851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deficiency of C-reactive protein or human C-reactive protein transgenic treatment aggravates influenza A infection in mice.
    Zhang Z; Gao Y; Li L; Luo J; Gao R
    Front Immunol; 2022; 13():1028458. PubMed ID: 36275680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-Reactive Protein Controls IL-23 Production by Human Monocytes.
    Geyer CE; Newling M; Sritharan L; Griffith GR; Chen HJ; Baeten DLP; den Dunnen J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Lowering of C-Reactive Protein.
    Jimenez RV; Szalai AJ
    Front Immunol; 2020; 11():619564. PubMed ID: 33633738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.